CCGB(SZ:300138)2025-01-21 08:16Financial Projections - The expected revenue for 2024 is projected to be between 689 million and 709 million yuan, representing a year-on-year growth of 0.27% to 3.18% compared to 687.15 million yuan in the previous year[3]. - The net profit attributable to shareholders is expected to be between 80 million and 115 million yuan, reflecting a significant decline of 83.32% to 76.03% from 479.72 million yuan in the previous year[4]. - The net profit after deducting non-recurring gains and losses is projected to be between 20 million and 55 million yuan, down 94.55% to 85.02% from 367.18 million yuan in the previous year[4]. - The specific financial data for 2024 will be disclosed in the annual report, urging investors to make cautious decisions and be aware of investment risks[14]. Business Development and Innovation - The company invested nearly 10 million yuan in process improvements for the cottonseed business, significantly enhancing the protein output ratio[6]. - The company launched a new extraction line for devil pepper, significantly increasing the production capacity of chili extract, further solidifying its industry-leading position[6]. - In 2024, the company obtained 48 authorized patents and participated in the application of 2 national key projects, leading 11 provincial projects[7]. - The company plans to increase the market share of its main products, aiming for a 1%-2% improvement in production yield for chili red pigment and to capture over 50% of the market share for chili oil resin[9]. - The company aims to achieve a global market share of 2/3 for silymarin by leveraging its technical and production advantages[9]. - The company will focus on promoting ginkgo leaf tablets in the traditional Chinese medicine sector to quickly achieve scale benefits[10]. - The company plans to integrate digital production management experiences and apply AI technologies to drive business growth[10]. - By 2025, the company aims to focus on major scientific research projects and key technology breakthroughs to enhance efficiency and reduce costs[11]. - The company plans to develop 2-3 scientifically formulated health food products annually, improving raw material bioavailability to support its health business[11]. - The company will strengthen patent layout and participate in the formulation and revision of national and industry standards to enhance industry leadership[11]. Talent and Management - The company emphasizes the importance of talent acquisition and development, planning to introduce and cultivate high-caliber personnel to drive innovation and industrial upgrades[13]. - The company intends to enhance the automation level in production workshops and improve management efficiency through detailed assessments of operational systems by 2025[12]. - The company will leverage its platform for planned investments, mergers, and shareholder structure optimization to manage market value and enhance corporate image[13]. - The company is committed to a safety management philosophy that emphasizes thorough inspections and addressing weak points to eliminate potential safety hazards[13].